Compare · SNY vs TAK
SNY vs TAK
Side-by-side comparison of Sanofi (SNY) and Takeda Pharmaceutical Company Limited (TAK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SNY and TAK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- SNY is the larger of the two at $105.75B, about 2.0x TAK ($52.09B).
- Over the past year, SNY is down 18.4% and TAK is up 8.9% - TAK leads by 27.3 points.
- TAK has been more active in the news (12 items in the past 4 weeks vs 8 for SNY).
- SNY has more recent analyst coverage (25 ratings vs 6 for TAK).
- Company
- Sanofi
- Takeda Pharmaceutical Company Limited
- Price
- $43.37+0.13%
- $16.53-0.18%
- Market cap
- $105.75B
- $52.09B
- 1M return
- -8.97%
- -9.33%
- 1Y return
- -18.38%
- +8.89%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 8
- 12
- Recent ratings
- 25
- 6
Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration with TrialSpark Inc. to execute clinical research studies in the areas of chronic obstructive pulmonary disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc, and Rani Therapeutics LLC; a license and research agreement with The University of Texas MD Anderson Cancer Center and Arrowhead Pharmaceuticals Inc.; a research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a strategic alliance with Egle Therapeutics SAS and Evotec SE; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer; and strategic collaboration with Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Latest SNY
- SEC Form 6-K filed by Sanofi
- Sanofi invests $294M to expand AI Center of Excellence in Toronto and accelerate innovation for patients
- Sanofi downgraded by Morgan Stanley
- SEC Form 6-K filed by Sanofi
- SEC Form 6-K filed by Sanofi
- SEC Form 6-K filed by Sanofi
- Sanofi downgraded by BNP Paribas Exane with a new price target
- SEC Form 6-K filed by Sanofi
- Sanofi becomes market authorization holder for Nuvaxovid® in Canada, expanding COVID-19 vaccine choices for Canadians
- SEC Form 6-K filed by Sanofi
Latest TAK
- British Columbia reimburses REVESTIVE® (teduglutide for injection) for the treatment of Short Bowel Syndrome
- SEC Form 3 filed by new insider Smoter Jennifer Marie
- Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
- President and CEO Weber Christophe Pierre was granted 78,900 units of Ordinary Shares and was granted 165,370 units of American Depositary Shares, decreasing direct ownership by 55% to 418,803 units (SEC Form 4) to cover taxes
- President, R&D Plump Andrew Stewart was granted 212,470 units of American Depositary Shares, increasing direct ownership by 36% to 806,572 units (SEC Form 4)
- Head, Strat. & Port. Dev. Pignagnoli Agosti Marcello was granted 27,740 units of American Depositary Shares, increasing direct ownership by 19% to 172,348 units (SEC Form 4)
- Chief Transformation Officer Duprey Lauren Rusckowski was granted 59,990 units of American Depositary Shares, increasing direct ownership by 36% to 228,503 units (SEC Form 4)
- CEO - Elect Kim Julie So-Young was granted 105,416 units of American Depositary Shares, increasing direct ownership by 32% to 430,145 units (SEC Form 4)
- Chief Data & Tech. Officer Ricci Gabriele was granted 34,994 units of American Depositary Shares, increasing direct ownership by 28% to 159,126 units (SEC Form 4)
- Chief Financial Officer Furuta Milano was granted 7,800 units of Ordinary Shares, increasing direct ownership by 16% to 57,900 units (SEC Form 4) (withholding obligation)